Erlotinib Combined With Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)

Sponsor
Zhejiang Cancer Hospital
Study ID
NCT01091376
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Erlotinib — DRUG
    Erlotinib 150mg/day
  • Thoracic radiotherapy — RADIATION
    60-70Gy/30-35f

Study Details

Concomitant chemoradiotherapy is the standard treatment of locally advanced,non-resectable, non-small cell lung cancer (NSCLC). However,the optimal chemotherapy regimen is still controversial.The objective of this study was to evaluate the efficacy and toxicity of a concomitant treatment using Erlotinib and radiotherapy followed by Erlotinib consolidation treatment.

Key Dates

First listed
Mar 24, 2010
Start date
Jan 31, 2010
Status verified
Mar 2010
Primary completion
Dec 31, 2010
Completion
Mar 31, 2013

Study Design

Enrollment
75 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Concomitant Erlotinib and radiotherapy
    Patients received Erlotinib and radiation therapy.

Primary Outcome Measure

Tumor response rate (Response was analyzed according to the RECIST system, based on CT scans.) [ Time Frame: After the thoracic radiotherapy and concurrent Erlotinib treatment ]

Central Contacts

Related Studies